Brain Mapping Instruments Market By Product Type (Electroencephalography (EEG), Functional Magnetic Resonance Imaging (fMRI), Magnetoencephalography (MEG), Positron Emission Tomography (PET), Computed Axial Tomography (CAT), Functional Near-Infrared Spectroscopy (fNIRS), Others), By Application (Clinical Diagnostics, Research, Surgical Planning, Neurorehabilitation, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Brain Mapping Instruments market accounted for USD 2.35 Billion in 2024 and is expected to reach USD 4.7 Billion by 2035, growing at a CAGR of around 6.5% between 2025 and 2035. The Brain Mapping Instruments Market refers to the area concerned with equipment and instruments applied for assessing and quantifying brain activity. This may involve diagnostic or research applications like EEG, fMRI, MEG, or TMS.

These are the instruments and devices applied for research and investigation of the functions of the brain and diagnostics and guidance of neurological treatment and treatment of such disorders as epilepsy, Alzheimer's disease, and stroke. The market is growing with increasing demand for neurological research, advances in neuroimaging techniques, and an increasing prevalence of brain-related disorders. Key drivers are technological innovation, growing healthcare applications, and population aging.

Report Scope:

Market Dynamics

Rising Prevalence of Neurological Disorders Driving Demand for Advanced Diagnostic Tools

The Increasing trend of neurological disease need for advanced diagnostic tools. Around 55 million people around the world are suffering from dementia, including Alzheimer's disease, which takes up about 60-70%, and other types of diseases, around 6 million people around the world are suffering from Parkinson's disease according to the report of the Parkinson's Foundation.

In the U.S. There are statistics given by the CDC that about 3.4 million people are believed to have epilepsy and 150,000 new cases per year have been diagnosed. thus, these figures highlight the rowing need for early detection coupled with efficient diagnostic technologies.

Therefore, governments are responding by creating and channeling research funds toward the development of early diagnostic tests for these disorders. Healthcare systems are also investing in integrating AI and advanced imaging technologies into their healthcare services to improve diagnostic accuracy and speed, addressing the growing demand for more effective neurological care.

Rising Investment in Neuroscience Research Fueling Growth in Brain-Diagnostic Tools and Therapies

The growing neuroscience research investment is majorly fueling the growth in the market for brain-diagnostic tools and therapies. The growth in funding from both private and government sectors is significant to understand and treat more effectively neurological disorders. Recently, the NIH has made a budget of over $2.7 billion for such research in the U.S. in 2023 primarily for neurological disease research in understanding Alzheimer's, Parkinson's, epilepsy, and so on.

Similarly, the European Union's Horizon 2020 program invested millions in joint research projects aimed at advancing neuroscience. Private sector investments are increasing as well, and with tech companies exploring AI and machine learning to find novel diagnostic solutions for neurological diseases, funding is surging that is accelerating breakthroughs in early detection, treatments, and diagnostic technologies, and further growth in the neuroscience market.

High Cost of Brain Mapping Technologies Barriers to Access and Innovation

The high technology costs of equipment such as fMRI and MEG create high barriers to the widespread use of the latter tools in hospitals and institutions carrying out research. High technology does need very specialized equipment, and high maintenance by specialized personnel, and many of them are costly. Many institutions cannot afford to have these tools, which limits their capacity to conduct cutting-edge neuroscience research or provide advanced diagnostic services.

The financial barrier can also limit access to these technologies, with the result that there may be disparities in healthcare and research opportunities, especially in institutions that are underfunded or smaller. As such, despite their potential to revolutionize the understanding of the brain, the high cost has been a major obstacle to their broader application.

Growing Demand and Innovation in Non-Invasive Brain Mapping Technologies

The rapid demand is seen in non-invasive brain mapping technologies like EEG (Electroencephalography) and TMS (Transcranial Magnetic Stimulation) due to their ability to monitor and modulate brain activity without requiring an invasive procedure.

Recent market reports have estimated that the global market for non-invasive brain stimulation devices would amount to nearly $701.14 million in 2024, and the market would show exponential growth in the coming years. This growth is being driven by increasing applications in treating conditions such as depression, anxiety, and chronic pain among neurological and psychiatric disorders.

In addition, the National Institutes of Health (NIH) in the U.S. has continued to actively fund research on non-invasive brain stimulation, especially to develop successful treatments and cognitive function enhancements. this sector avails strong innovation potential, which sets the stage for new technologies that will alter both clinical practices and neuroscience research.

Research-Driven Growth Opportunities in Brain Mapping for Neurodegenerative Diseases

The increasing interest in understanding brain function and cognitive abilities, particularly in neurodegenerative diseases like Alzheimer's and Parkinson's, offers great growth opportunities for brain mapping technologies. In 2023, the National Institute on Aging (NIA) allocated over $3.8 billion for Alzheimer's disease research alone, with much of the funding directed toward improving diagnostic tools, early detection, and treatment interventions.

In addition, the NIH committed around $1.9 billion to neurodegenerative disease research in 2022, which includes funding for advanced brain imaging and cognitive function studies. This increase in government investment clearly shows the growing priority to understand cognitive decline and the mechanisms behind it.

The availability of technologies like fMRI and PET scans enable the tracing of progression, for example, that may be taking place with a disease such as Alzheimer's. This could mean a significant opening to earlier diagnoses, thereby creating better possibilities for effective treatment. Thus, the trends in funding look bright and suggest much room for research-driven growth within this area of research.

Industry Experts Opinion

"Addressing the well-being of our minds and taking preventive measures is like securing a roadmap for what lies ahead. It's not just about responding when issues arise; it's about proactively fostering a mindset of prevention against neurological conditions," 

• Prof. Wolfgang Grisold, President of WFN.

"Neuroscience is one of our key growth areas and we are committed to driving innovation in this field to address critical unmet needs for patients living with seriously debilitating neurological diseases such as Alzheimer's disease,"

• Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer, AbbVie.

Segment Analysis

Based on product type, the Brain Mapping Instruments market includes technologies such as Electroencephalography (EEG), Functional Magnetic Resonance Imaging (fMRI), Magnetoencephalography (MEG), Positron Emission Tomography (PET), Computed Axial Tomography (CAT), and Functional Near-Infrared Spectroscopy (fNIRS). Among these, fMRI is the leading technology due to its non-invasive nature and ability to provide detailed, real-time images of brain activity, making it highly valuable for both clinical diagnostics and neuroscience research.

Based on application, the Brain Mapping Instruments market includes Clinical Diagnostics, Research, Surgical Planning, Neurorehabilitation, and Others. Clinical Diagnostics leads due to the growing need for non-invasive tools to diagnose and monitor neurological conditions like epilepsy and Alzheimer's.

Regional Analysis

The Brain Mapping Instruments market is dominated by North America, led by the advanced healthcare infrastructure and high research funding. Some of the top neuroscience research institutions are located in North America. The U.S. invests heavily in brain-related research, with funding from the NIH for projects such as cutting-edge neuroscience projects.

Demand for brain mapping technologies in clinical diagnostics for neurological disorders like Alzheimer's and epilepsy further propels the market growth. This dominance in the market is supported by the well-established health systems within this region and the growing focus on mental health and cognitive disorders. In addition, the strong regulatory environment and high usage of advanced imaging techniques in North America will support the growth of brain mapping technologies.

Asia Pacific is the fastest-growing region for the Brain Mapping Instruments market, mainly because of technological advances, increased healthcare investments, and a growing interest in neurological research. Countries such as China, Japan, and India are expanding their healthcare capacities and research initiatives, encouraged by government funding and innovative capabilities from the private sector.

With an increase in neurological conditions and the adoption of advanced diagnostics, brain mapping technologies are in big demand. Asia Pacific leads as the region for growth in a global market. Improving healthcare access and increasing public awareness of mental health is expected to further accelerate its growth.

Competitive Landscape

The brain mapping instruments market is highly competitive, with the key players being Medtronic PLC, Philips Healthcare, Siemens Healthineers, GE Healthcare, Neuroelectrics, and Compumedics Limited. These companies have pioneered advanced neuroimaging technologies such as EEG, fMRI, and MEG systems. Recent developments include deep brain stimulation (DBS) device advancements from Medtronic.

DBS devices are used in tandem with brain mapping for treating neurological disorders. Neuroelectrics recently released a new generation of wearable EEG systems for the real-time monitoring of brain activity and has improved personalized treatment. Siemens Healthineers released AI-based tools to read brain scans more efficiently. Such companies that are in high demand for state-of-the-art neurodiagnostic tools are now turning towards more product innovation and strategic partnerships to increase their market shares. Recent advancements in AI and ML are further intensifying the competition through improved data analysis and real-time brain activity interpretation.

Brain Mapping Instruments Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In July 2024, Brain Products GmbH released BrainVision Analyser 2.3.0.8301, a software for processing EEG and ERP data. It supports over 50 formats, includes MATLAB integration, and offers scientific output and technical support.
• In January 2024, Medtronic received FDA approval for its Percept RC Deep Brain Stimulation system, expanding its portfolio with a rechargeable neurostimulator and BrainSense technology.

Report Coverage:

By Product Type

• Electroencephalography (EEG)
• Functional Magnetic Resonance Imaging (fMRI)
• Magnetoencephalography (MEG)
• Positron Emission Tomography (PET)
• Computed Axial Tomography (CAT)
• Functional Near-Infrared Spectroscopy (fNIRS)
• Others

By Application

• Clinical Diagnostics
• Research
• Surgical Planning
• Neurorehabilitation
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies

• Medtronic PLC
• GE Healthcare
• Philips Healthcare
• Siemens Healthineers
• Brain Products GmbH
• Nihon Kohden Corporation
• NeuroSky, Inc.
• Compumedics Limited
• Biosemi
• Advanced Brain Monitoring, Inc.
• Cortech Solutions, Inc.
• QIAGEN
• Electrical Geodesics, Inc.
• Magstim
• Cognionics, Inc.

Frequently Asked Questions (FAQs)